Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

Documenti analoghi

• Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
  di: Amita Datta‐Mannan, et al.
  Pubblicazione: (2024)
• Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends
  di: Jason Boer, et al.
  Pubblicazione: (2026)
• Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
  di: Divya Samineni, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
  di: Ziheng Hu, et al.
  Pubblicazione: (2026)
• Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled Study
  di: Amita Datta‐Mannan, et al.
  Pubblicazione: (2024)